Related Experiment Video

Updated: Mar 14, 2026

A New Toolkit for Evaluating Gene Functions using Conditional Cas9 Stabilization
08:20

A New Toolkit for Evaluating Gene Functions using Conditional Cas9 Stabilization

Published on: September 2, 2021

4.7K

CRISPR-Cas9 therapeutics in cancer: promising strategies and present challenges

Lang Yi1, Jinming Li1

  • 1National Center for Clinical Laboratories, Beijing Hospital, National Center of Gerontology, Beijing, People's Republic of China; Graduate School, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, People's Republic of China; Beijing Engineering Research Center of Laboratory Medicine, Beijing Hospital, Beijing, People's Republic of China.

Biochimica Et Biophysica Acta
|September 20, 2016
PubMed

Insights

CRISPR-Cas9 genome editing shows promise for cancer therapy by correcting mutations and enhancing immune cells. This review covers preclinical strategies and discusses challenges for clinical translation.

Area of Science:

  • Oncology
  • Genetics
  • Biotechnology

Background:

  • Cancer involves genetic and epigenetic changes leading to proliferation and chemoresistance.
  • Correcting or eliminating cancer-driving mutations offers therapeutic potential.
  • CRISPR-Cas9 genome editing is a powerful tool for cancer research and therapy.

Purpose of the Study:

  • To summarize preclinical CRISPR-Cas9-based therapeutic strategies for cancer.
  • To discuss challenges and improvements for clinical translation of CRISPR-Cas9 cancer therapies.
  • To propose future directions for CRISPR-Cas9 in cancer treatment.

Main Methods:

  • Review of preclinical studies utilizing CRISPR-Cas9 for cancer therapy.
  • Analysis of CRISPR-Cas9 applications in targeting cancer cell DNA.
  • Examination of CRISPR-Cas9 roles in oncogenic infections, drug discovery, and immunotherapy.

Main Results:

  • CRISPR-Cas9 demonstrates therapeutic potential in cellular and animal cancer models.
  • Applications include direct targeting of cancer DNA, fighting infections, drug exploration, and immune cell engineering.
  • Preclinical successes highlight the expanding utility of CRISPR-Cas9 in oncology.

Conclusions:

  • CRISPR-Cas9-based strategies show significant preclinical promise for cancer treatment.
  • Addressing challenges is crucial for successful clinical translation of these genome editing therapies.
  • Further research into CRISPR-Cas9 holds potential for advancing cancer therapy and research.
Keywords:
CRISPR-Cas9Cancer genome manipulationCancer therapyGene therapyGenome editing

More Related Videos

Using CRISPR/Cas9 to Knock Out GM-CSF in CAR-T Cells07:56

Using CRISPR/Cas9 to Knock Out GM-CSF in CAR-T Cells

Published on: July 22, 2019

12.0K
Using CRISPR/Cas9 Gene Editing to Investigate the Oncogenic Activity of Mutant Calreticulin in Cytokine Dependent Hematopoietic Cells10:21

Using CRISPR/Cas9 Gene Editing to Investigate the Oncogenic Activity of Mutant Calreticulin in Cytokine Dependent Hematopoietic Cells

Published on: January 5, 2018

13.8K

Related Concept Videos

CRISPR01:59

CRISPR

Genome editing technologies allow scientists to modify an organism’s DNA via the addition, removal, or rearrangement of genetic material at specific genomic locations. These types of techniques could potentially be used to cure genetic disorders such as hemophilia and sickle cell anemia. One popular and widely used DNA-editing research tool that could lead to safe and effective cures for genetic disorders is the CRISPR-Cas9 system. CRISPR-Cas9 stands for Clustered Regularly Interspaced...
58.7K
CRISPR01:59

CRISPR

18.8K
CRISPR/Cas9 Genome Editing01:28

CRISPR/Cas9 Genome Editing

The CRISPR-Cas system serves as a bacterial defense mechanism against invading genetic elements such as viruses and plasmids, forming the foundation for its adaptation as a powerful genome-editing tool. Originally discovered in prokaryotes, this system has been repurposed to revolutionize genetic engineering across a wide range of organisms, including plants, animals, and humans. The core component, Cas9, is an endonuclease derived from Streptococcus pyogenes, capable of introducing...
2.4K
CRISPR and crRNAs02:53

CRISPR and crRNAs

Bacteria and archaea are susceptible to viral infections just like eukaryotes; therefore, they have developed a unique adaptive immune system to protect themselves. Clustered regularly interspaced short palindromic repeats and CRISPR-associated proteins (CRISPR-Cas) are present in more than 45% of known bacteria and 90% of known archaea.
The CRISPR-Cas system stores a copy of foreign DNA in the host genome and uses it to identify the foreign DNA upon reinfection. CRISPR-Cas has three different...
19.5K
Homologous Recombination02:31

Homologous Recombination

The basic reaction of homologous recombination (HR) involves two chromatids that contain DNA sequences sharing a significant stretch of identity. One of these sequences uses a strand from another as a template to synthesize DNA in an enzyme-catalyzed reaction. The final product is a novel amalgamation of the two substrates. To ensure an accurate recombination of sequences, HR is restricted to the S and G2 phases of the cell cycle. At these stages, the DNA has been replicated already and the...
65.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K